- Slice of Manufacturing
- Posts
- Amsino International Acquires MedXL Assets to Enhance Manufacturing
Amsino International Acquires MedXL Assets to Enhance Manufacturing
Slice of Manufacturing Team
December 02, 2024
Key Highlights:
Amsino acquires MedXL's assets, including IP, facilities, and product registrations in 60+ countries.
MedXL specializes in prefilled syringes for intravenous drug therapy.
Acquisition aligns with Amsino's reshoring strategy and supply chain resiliency goals.
Combined manufacturing capacity to exceed 500 million syringe units annually.
Innovative MedXL products include Praxiject™, CitraFlow™, and CitraFlow PLUS™ syringes.
Source: PR Newswire
Notable Quotes:
"The acquisition aligns perfectly with our reshoring strategy to expand our manufacturing footprint to better serve customers in North America."
"Amsino will immediately have both onshore and offshore plants to manufacture existing and new prefilled syringes with an annual combined capacity of more than 500 million units."
"We see great synergy between MedXL's product portfolio, Amsino's strategic goals and its US and global distribution channels."
Our Take:
This acquisition signifies a pivotal moment in Amsino International’s growth trajectory. By integrating MedXL's state-of-the-art facilities and product portfolio, Amsino reinforces its commitment to supply chain resiliency and innovation in intravenous drug therapy. MedXL’s FDA and globally certified facilities provide Amsino with a competitive edge in North America and beyond, particularly in a healthcare environment increasingly focused on onshore manufacturing and product reliability. This move is likely to solidify Amsino's leadership in the prefilled syringe market while ensuring robust service capabilities across its customer base.